Marshall Wace
IOVA icon

Marshall Wace’s Iovance Biotherapeutics IOVA Stock Holding History

Marshall Wace’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$164K Sell
39,491
-2,316,121
-98% -$8.8M ﹤0.01% 2860
2026
Q1 		$8.27M Buy
+2,355,612
New +$7.53M 0.01% 1065
2025
Q3 		– Sell
-111,200
Closed -$191K – 3121
2025
Q2 		$191K Buy
111,200
+71,558
+181% +$178K ﹤0.01% 2464
2025
Q1 		$132K Sell
39,642
-1,090,813
-96% -$5.63M ﹤0.01% 2466
2024
Q4 		$8.37M Buy
+1,130,455
New +$10.5M 0.01% 861
2024
Q3 		– Sell
-1,612,055
Closed -$12.9M – 2726
2024
Q2 		$12.9M Buy
+1,612,055
New +$17.3M 0.02% 625
2023
Q4 		– Sell
-35,011
Closed -$159K – 2378
2023
Q3 		$159K Buy
+35,011
New +$229K ﹤0.01% 2004
2023
Q1 		– Sell
-369,463
Closed -$2.36M – 2873
2022
Q4 		$2.36M Buy
+369,463
New +$2.88M 0.01% 1636
2022
Q2 		– Sell
-50,953
Closed -$848K – 3638
2022
Q1 		$848K Sell
50,953
-810,207
-94% -$12.5M ﹤0.01% 2522
2021
Q4 		$16.4M Buy
+861,160
New +$19M 0.03% 575
2021
Q3 		– Sell
-17,867
Closed -$465K – 3216
2021
Q2 		$465K Sell
17,867
-23,932
-57% -$622K ﹤0.01% 2165
2021
Q1 		$1.32M Buy
+41,799
New +$1.73M 0.01% 1522
2020
Q4 		– Sell
-58,026
Closed -$1.91M – 2018
2020
Q3 		$1.91M Buy
58,026
+30,635
+112% +$939K 0.01% 821
2020
Q2 		$752K Buy
+27,391
New +$900K 0.01% 1083
2020
Q1 		– Sell
-1,949
Closed -$54K – 1846
2019
Q4 		$54K Buy
+1,949
New +$44.3K ﹤0.01% 1536
2019
Q2 		– Sell
-566,016
Closed -$5.38M – 1572
2019
Q1 		$5.38M Buy
566,016
+80,510
+17% +$782K 0.05% 454
2018
Q4 		$4.3M Buy
+485,506
New +$4.68M 0.04% 491
2018
Q2 		– Sell
-28,991
Closed -$490K – 761
2018
Q1 		$490K Buy
+28,991
New +$439K 0.02% 367

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Marshall Wace's IOVA Position: Q2 2026 in Review

Marshall Wace reduced its Iovance Biotherapeutics (IOVA) stake by 98% in Q2 2026, selling an estimated $8.8M and leaving 39,491 shares worth $164K. The position accounts for ﹤0.01% of the portfolio, ranked #2860.

Marshall Wace first reported a position in IOVA in Q1 2018 and has held it in 18 quarters since. The position peaked at $16.4M in Q4 2021. 293 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • Marshall Wace held 39,491 shares of Iovance Biotherapeutics worth $164K as of Q2 2026.
  • Marshall Wace sold 2,316,121 Iovance Biotherapeutics shares in Q2 2026, an estimated $8.8M.
  • Iovance Biotherapeutics made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #2860 holding.
  • Marshall Wace first reported a position in Iovance Biotherapeutics in Q1 2018 and has held it in 18 quarters since.
  • Marshall Wace's Iovance Biotherapeutics position peaked at $16.4M in Q4 2021.
  • 293 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.